# A Study to Evaluate in Patients With Parkinsonian Type Disorders

> **NCT03683225** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chase Therapeutics Corporation** · enrollment: 24 (estimated)

## Conditions studied

- Idiopathic Parkinson Disease

## Interventions

- **COMBINATION_PRODUCT:** CTC-413

## Key facts

- **NCT ID:** NCT03683225
- **Lead sponsor:** Chase Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03683225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03683225, "A Study to Evaluate in Patients With Parkinsonian Type Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03683225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*